Abstracts tagged "B cells"

Abstract Number: 1742 • 2012 ACR/ARHP Annual Meeting
A Novel Murine Model of B Cell-Mediated Proteinuria Suggests Cytokines Mediate Podocyte Injury
Alfred Kim¹ and Andrey S. Shaw², ¹IM/Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ²Pathology & Immunology/HHMI, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: B cell depletion therapies have been efficacious in several glomerulopathies. The contributions of B cells to proteinuria and foot process effacement remain unknown. The…
Abstract Number: 835 • 2012 ACR/ARHP Annual Meeting
Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients
Adrienne O'Reilly, Tracy Davis and Vinay Jain, Mentrik Biotech, Dallas, TX
Background/Purpose: B-cell depletion provides therapeutic benefits for patients with rheumatoid arthritis (RA). Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered, humanized, anti-CD20…
Abstract Number: 2316 • 2012 ACR/ARHP Annual Meeting
Generation of CD4⁺ Follicular Helper Tcells by Complement and Immune Complexes
Anil K. Chauhan¹, Richard DiPaolo² and Terry L. Moore³, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Molecular Microbiology and Immunology, Saint Louis, MO, ³Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: Complement opsonized immune complexes (ICs) are key players of disease pathology. We showed in systemic lupus erythematosus (SLE), ICs and complement (C’) drive activation…
Abstract Number: 1743 • 2012 ACR/ARHP Annual Meeting
IL-5-Induced FasL⁺ Regulatory B Cells Are Inhibited by IL-4 and Cyclosporine
Matthew W. Klinker¹, Brian R. Alzua¹, Tamra J. Reed², David A. Fox³ and Steven K. Lundy⁴, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology/Int Medicine, Univ of Michigan Med Ctr, Ann Arbor, MI, ⁴Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: We previously identified a subset of regulatory B cells that express the apoptosis-inducing molecule Fas ligand (FasL), and reported that these B cells were…
Abstract Number: 674 • 2012 ACR/ARHP Annual Meeting
Altered Response to B Cell Receptor (BCR) Crosslinking in SLE: Correlation with Genetic Risk Variants Predicted to Impact BCR Signaling
Nan-Hua Chang¹, Timothy Li², Paul R. Fortin³, Dafna D. Gladman⁴, Carolina Landolt-Marticorena⁵, Jorge Sanchez-Guerrero⁶, Murray B. Urowitz⁷ and Joan E. Wither⁸, ¹Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, ³University of Laval, Quebec, QC, Canada, ⁴Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸1E420/Div of Rheumatology, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Altered B cell signaling has been proposed to play an important role in susceptibility to SLE. In mice, genetic manipulations or polymorphisms that attenuate…
Abstract Number: 2666 • 2012 ACR/ARHP Annual Meeting
A Link Between B Cells and Bone Erosion in RA: RANKL Production by Memory B Cells
Nida Meednu¹, Teresa Owen², Hengwei Zhang³, Christopher A. Cistrone¹, Lianping Xing⁴ and Jennifer H. Anolik⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Allergy, Immununolgy and Rheumatology,, University of Rochester, Rochester, NY, ³Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disorder that often leads to joint damage. Several lines of evidence suggests the role of B cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].